Compare Progressive Corp (PGR) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Progressive Corp vs Zoetis Inc — how do they compare? Progressive Corp trades at $215.8 (market cap $125.23B), while Zoetis Inc trades at $73.65 (market cap $30.29B). The key difference: Progressive Corp is far larger — about 4.1× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| PGR | ZTS | |
|---|---|---|
Market Cap | $125.23B | $30.29B |
Sector | Financials | Health |
52-Week High | $248.80 | $150.61 |
52-Week Low | $190.40 | $71.91 |
Enterprise Value | $133.44B | $37.86B |
Dividend Yield | 0.19% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Progressive (PGR) trades at $214.9, down 1.85% today, with a bearish technical signal and neutral oscillators. The stock shows strong fundamentals with a P/E of 10.78, net income margin of 12.85%, and ROE of 34.94%, supported by revenue growth from $49.6B in 2022 to $87.6B in 2025. Recent earnings beat expectations in Q4 2025 and Q2 2026, but missed in Q1 2026. News highlights competition in auto insurance and telematics advantages.
Outlook is mixed: analyst consensus targets $231.18 with 38.1% buy ratings, but technical weakness and competitive pressures pose risks. Investment opportunity lies in valuation discounts and operational strength, though expense increases and market volatility require caution.
Zoetis (ZTS) trades at $73.6, down 2.92% on the day, near its 52-week low amid bearish technical signals. The stock shows strong fundamentals with a P/E of 12, net margin of 27.69%, and consistent earnings beats, but faces headwinds from weak U.S. companion animal sales and reduced 2026 guidance. Recent news includes an FDA emergency use authorization for Simparica Trio and participation in healthcare conferences.
The outlook is mixed: valuation appears attractive with a consensus price target of $93.40, but near-term risks include competitive pressures and soft pet health demand. Long-term investors may find value in its profitability and market dominance, though volatility persists from sector challenges and investor sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
